Final LGBTQ Individuals in clinical research

Send us Fan Mail

Support the show

www.kulkarnilawfirm.com

Episode Transcript

Darshan (00:00):
Today we're gonna talk about clinical trial sponsors

(00:02):
and about a critical segment inthe population.
LGBTQ community.
Now, I know the current climate,but the change in the
administration, the FTA'sdiversity action plans, the
DAPs, have been deprioritized.
Certain LGBTQ requirements wereeven withdrawn.
I might be tempted to think thisis the problem for later.
Here's the reality.
LGBTQ individuals are your endusers, but Gen Z identifying as

(00:27):
much as 20% as LGBTQ, ignoringthis community means you're
essentially excluding yourselffrom one-fifth of your future
markets.
At the Cole County Law Firm, wehelp you think five to ten years
ahead.
Fact is that career scientistsat the FDA, the deep state, if
you will, they aren't goinganywhere.
If you submit a study years fromnow that lacks representative

(00:47):
data, you risk massive costs andunavoidable delays.
Why move your own finish linewhen you can plan for this
upfront and you can actually beproactive about this?
Furthermore, when a drugapproval hangs by a thread, you
want most organized advocates inyour corner.
LGBTQ communities are actuallyexceptionally well at being
organized.
This can be the differencebetween a yes and a no from the

(01:09):
FDA.

SPEAKER_00 (01:13):
Enjoying our content, we'd love to hear more.
Please like, comment, share, andfind more.

Darshan (01:21):
This is about better science.
If you aren't asked the rightquestions about hormones or
biology, you're missing criticalsafety data.
Like the increased risk of bloodclots.
For patients on estrogen, forexample, inclusion also drives
retention.
If your clinical study sitedoesn't know how to respectfully
engage, if they use the wrongpronouns, if they make
exclusionary assumptions, yourparticipants leave.

(01:42):
And with that, your customersleave.
That is lost data and a failstrategy.
Pause in federal mandates isactually your opportunity to
restrategize to build a biggerfunnel.
At the Kilkarney Law Firm, wefocus on FDA regulatory law and
compliance, and we ensure thatyour research is both
scientifically rigorous andfuture-proof.

(02:04):
Don't just meet the minimum,lead the field.
If you found this insight to bevaluable, please subscribe to
Darchan Talk for more deepdives.
For legal guidance on yourclinical trial strategy, visit
us at KilkarnelawFirm.com.
Thanks for listening.
Call, click, or email.